Last reviewed 2026-06-01 · How we verify

lobaplatin , 5-FU ,leucovorin

Taian Cancer Hospital · Phase 3 active Small molecule Under review

lobaplatin , 5-FU ,leucovorin is a Platinum-based chemotherapy Small molecule drug developed by Taian Cancer Hospital. It is currently in Phase 3 development for Metastatic colorectal cancer, Metastatic gastric cancer. Also known as: LBP ,5-FU,LV.

Lobaplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.

Lobaplatin is used in combination with 5-FU and leucovorin as part of the Folfox Protocol, which is studied for treating conditions such as Hepatocellular Carcinoma, Esophageal Carcinoma, and HepatoCellular Carcinoma. Hepatic arterial infusion and transarterial chemoembolization are also studied interventions for these conditions.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	lobaplatin , 5-FU ,leucovorin
Also known as	LBP ,5-FU,LV
Sponsor	Taian Cancer Hospital
Drug class	Platinum-based chemotherapy
Target	DNA
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

Lobaplatin is a second-generation platinum compound that has been shown to be more potent than cisplatin in some preclinical studies. It is thought to exert its antitumor effects by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.

Approved indications

Metastatic colorectal cancer
Metastatic gastric cancer

Common side effects

Myelosuppression
Nausea and vomiting
Diarrhea
Neutropenia
Thrombocytopenia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

lobaplatin , 5-FU ,leucovorin CI brief — competitive landscape report
lobaplatin , 5-FU ,leucovorin updates RSS · CI watch RSS
Taian Cancer Hospital portfolio CI

Frequently asked questions about lobaplatin , 5-FU ,leucovorin

What is lobaplatin , 5-FU ,leucovorin?

lobaplatin , 5-FU ,leucovorin is a Platinum-based chemotherapy drug developed by Taian Cancer Hospital, indicated for Metastatic colorectal cancer, Metastatic gastric cancer.

How does lobaplatin , 5-FU ,leucovorin work?

Lobaplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.

What is lobaplatin , 5-FU ,leucovorin used for?

lobaplatin , 5-FU ,leucovorin is indicated for Metastatic colorectal cancer, Metastatic gastric cancer.

Who makes lobaplatin , 5-FU ,leucovorin?

lobaplatin , 5-FU ,leucovorin is developed by Taian Cancer Hospital (see full Taian Cancer Hospital pipeline at /company/taian-cancer-hospital).

Is lobaplatin , 5-FU ,leucovorin also known as anything else?

lobaplatin , 5-FU ,leucovorin is also known as LBP ,5-FU,LV.

What drug class is lobaplatin , 5-FU ,leucovorin in?

lobaplatin , 5-FU ,leucovorin belongs to the Platinum-based chemotherapy class. See all Platinum-based chemotherapy drugs at /class/platinum-based-chemotherapy.

What development phase is lobaplatin , 5-FU ,leucovorin in?

lobaplatin , 5-FU ,leucovorin is in Phase 3.

What are the side effects of lobaplatin , 5-FU ,leucovorin?

Common side effects of lobaplatin , 5-FU ,leucovorin include Myelosuppression, Nausea and vomiting, Diarrhea, Neutropenia, Thrombocytopenia.

What does lobaplatin , 5-FU ,leucovorin target?

lobaplatin , 5-FU ,leucovorin targets DNA and is a Platinum-based chemotherapy.

Drug class: All Platinum-based chemotherapy drugs
Target: All drugs targeting DNA
Manufacturer: Taian Cancer Hospital — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Metastatic colorectal cancer
Indication: Drugs for Metastatic gastric cancer
Also known as: LBP ,5-FU,LV

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing